NVIDIA
NVDA
Tesla
TSLA
Taiwan Semiconductor
TSM
4
Palantir
PLTR
5
Super Micro Computer
SMCI
US Stock MarketDetailed Quotes
EVOK Evoke Pharma
- 3.9600
- +0.3364+9.28%
Close Mar 4 16:00 ET
- 3.9600
- 0.00000.00%
Post 20:01 ET
5.88MMarket Cap-0.39P/E (TTM)
4.3700High3.6700Low11.41KVolume3.7400Open3.6236Pre Close44.63KTurnover0.90%Turnover RatioLossP/E (Static)1.49MShares12.319952wk High1.34P/B5.03MFloat Cap3.440052wk Low--Dividend TTM1.27MShs Float2052.0000Historical High--Div YieldTTM19.32%Amplitude3.4400Historical Low3.9130Avg Price1Lot Size
Evoke Pharma Stock Forum
anyone got any news?
📊⚡️📊
Benzinga· 2 mins ago
FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025
Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related costs compared to...
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends
Thursday, 19th December at 8:30 am
FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025
Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related costs compared to oral metoclopramide
SOLANA BEACH, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Phar...
Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®
Tuesday, 3rd December at 8:30 am
SOLANA BEACH, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it has received notices of allowance for two U.S. patent appli...
Evoke Pharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Laurence W. Lytton(9.99%)
will it ever rise?
No comment yet